# OnCo record duboce-biopharmaceuticals (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/duboce-biopharmaceuticals/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "duboce-biopharmaceuticals" ;
  schema:name "Duboce Biopharmaceuticals"@en ;
  schema:alternateName "Duboce Biopharmaceuticals, Inc."@en ;
  schema:description "Duboce Biopharmaceuticals is developing DBC-664, an antibody that links the immune system's T cells to cancer cells carrying the proteins ALPP or ALPPL2, which are common in ovarian and endometrial cancers. It is in a first human trial."@en ;
  schema:url <https://onco.cc/companies/duboce-biopharmaceuticals/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.tcglsoleil.com/news/tcg-labs-soleil-highlights-portfolio-momentum-with-three-programs-entering-first-in-human-clinical-trials-across-oncology-and-cardiovascular-disease/>, <https://clinicaltrials.gov/study/NCT07705035> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/ovarian/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/lung-adenocarcinoma/>, <https://onco.cc/cancers/urothelial/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/cd3/> .